Galaxy Biotech LLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Galaxy Biotech LLC
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
Cardiome may go it alone with atrial fibrillation drug vernakalant after Merck exited a 2009 partnership around the drug, but another possibility is that Cardiome will seek a buyer.
Roche has licensed exclusive worldwide development and commercialisation rights to Galaxy Biotech's antibodies targeting fibroblast growth factor 2 (FGF2) for the treatment of cancer.
- Large Molecule